Cambridge, UK, 15 Feb 2020: The o2h Therapeutics and AI Fund (“The Fund”), an early stage S/EIS fund investing in biotechnology therapeutics and related AI opportunities, is pleased to announce an investment in Neurofenix, an innovative digital health company empowering stroke survivors and their families to get their life back.
Strokes are currently the single largest cause of adult disability, with over 1.5 million stroke survivors in the UK alone. However because of under resourced public health care systems and the high costs of private physiotherapy, many survivors are unable to recover to their full potential.
Neurofenix is aiming to make rehabilitation more autonomous, enjoyable and accessible to stroke victims and have launched a first-of-its-kind gaming device that has been shown to significantly improve the outcomes of stroke survivors by helping them regain strength and movement in their arms and hands
This is o2h Ventures first investment in the digital therapeutics space. This is an emerging area and fits one of the three buckets that the Fund invests into. o2h see’s great opportunities in this area where technology meets biotechnology and given the UK’s strong foundation in both these disciplines, o2h Ventures are well positioned to take advantage of this.
Sunil Shah, CEO, o2h Ventures who manages The Fund alongside Prashant Shah, said, “We have evaluated lots of opportunities in the digital therapeutics space and this was by far the most attractive, it is a genuine use of AI to help stroke patients. The product is already available in the UK and they have shipped over 200 units with positive patient feedback.”
Guillem Singla Buxarrais, Co-Founder and CEO of Neurofenix, added, “We are really excited to have o2h Ventures as an investor in this round, they showed great passion for our product and their industry-specific networks will be valuable to help us create partnerships to grow the business to provide the world’s best home rehabilitation experience to stroke patients”.
About o2h Ventures:
o2h Ventures Limited has launched the o2h Therapeutics and AI fund which is the first S/EIS fund in the UK solely focused on early stage biotech therapeutics and related AI opportunities. The geographic scope shall be UK wide including Oxford and London but will target the growing Cambridge biotech cluster. The Fund is structured to be S/EIS compliant providing tax breaks for UK taxpayers.
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h operate from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.
For more information or to invest in the fund, please visit- www.o2hventures.com
The mission of Neurofenix is to transform stroke care delivery.
At Neurofenix we believe upper limb recovery after stroke is unacceptably poor.
We are a multidisciplinary team of highly qualified and motivated professionals who want to make a difference in the lives of stroke survivors and their families.
We worked together with stroke survivors, their families, therapists and physicians from day one to design an easy to use upper limb training device that costs a fraction of its closest competitors. The Neurofenix NeuroBall can be used with little or no supervision, making it ideal for both survivors as well as therapists who want to maximise their patient’s potential in between sessions.
We have already received a lot of interest and enthusiasm from stroke associations, private clinics and the NHS. If you are interested in becoming an investor or in partnering with us, please get in touch.
Guillem Singla Buxarrais
Co-Founder and CEO